These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 21660045)
1. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Bae J; Carrasco R; Lee AH; Prabhala R; Tai YT; Anderson KC; Munshi NC Leukemia; 2011 Oct; 25(10):1610-9. PubMed ID: 21660045 [TBL] [Abstract][Full Text] [Related]
2. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Bae J; Smith R; Daley J; Mimura N; Tai YT; Anderson KC; Munshi NC Clin Cancer Res; 2012 Sep; 18(17):4850-60. PubMed ID: 22753586 [TBL] [Abstract][Full Text] [Related]
3. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Bae J; Prabhala R; Voskertchian A; Brown A; Maguire C; Richardson P; Dranoff G; Anderson KC; Munshi NC Leukemia; 2015 Jan; 29(1):218-29. PubMed ID: 24935722 [TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Bae J; Hideshima T; Zhang GL; Zhou J; Keskin DB; Munshi NC; Anderson KC Leukemia; 2018 Mar; 32(3):752-764. PubMed ID: 29089645 [TBL] [Abstract][Full Text] [Related]
5. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Bae J; Samur M; Munshi A; Hideshima T; Keskin D; Kimmelman A; Lee AH; Dranoff G; Anderson KC; Munshi NC Oncoimmunology; 2014; 3(12):e970914. PubMed ID: 25941601 [TBL] [Abstract][Full Text] [Related]
6. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Bae J; Martinson JA; Klingemann HG Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068 [TBL] [Abstract][Full Text] [Related]
7. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Bae J; Tai YT; Anderson KC; Munshi NC Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685 [TBL] [Abstract][Full Text] [Related]
8. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Bae J; Song W; Smith R; Daley J; Tai YT; Anderson KC; Munshi NC Br J Haematol; 2012 Jun; 157(6):687-701. PubMed ID: 22533610 [TBL] [Abstract][Full Text] [Related]
9. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma. Kang YJ; Zeng W; Song W; Reinhold B; Choi J; Brusic V; Yamashita T; Munshi A; Li C; Minvielle S; Anderson KC; Munshi N; Reinherz EL; Sasada T Br J Haematol; 2013 Nov; 163(3):343-51. PubMed ID: 24032635 [TBL] [Abstract][Full Text] [Related]
10. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Harig S; Witzens M; Krackhardt AM; Trojan A; Barrett P; Broderick R; Zauls AJ; Gribben JG Blood; 2001 Nov; 98(10):2999-3005. PubMed ID: 11698283 [TBL] [Abstract][Full Text] [Related]
11. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735 [TBL] [Abstract][Full Text] [Related]
12. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 Bae J; Samur M; Richardson P; Munshi NC; Anderson KC Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779 [TBL] [Abstract][Full Text] [Related]
13. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595 [TBL] [Abstract][Full Text] [Related]
14. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Bae J; Martinson JA; Klingemann HG Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513 [TBL] [Abstract][Full Text] [Related]
15. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571 [TBL] [Abstract][Full Text] [Related]